Total Payments
$15,247
2024 Payments
$1,934
Companies
61
Transactions
906
Medicare Patients
22,457
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$15,126 (99.2%)
Education$107.85 (0.7%)
Other$13.33 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,126 | 898 | 99.2% |
| Education | $107.85 | 7 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13.33 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,949 | 101 | $0 (2024) |
| Novo Nordisk Inc | $1,882 | 116 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,284 | 65 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,201 | 71 | $0 (2024) |
| PFIZER INC. | $1,032 | 68 | $0 (2024) |
| ABBVIE INC. | $1,017 | 54 | $0 (2024) |
| Lilly USA, LLC | $828.22 | 67 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $770.85 | 69 | $0 (2024) |
| Allergan, Inc. | $505.18 | 36 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $504.58 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,934 | 101 | GlaxoSmithKline, LLC. ($306.68) |
| 2023 | $2,157 | 123 | GlaxoSmithKline, LLC. ($389.09) |
| 2022 | $2,132 | 123 | ABBVIE INC. ($284.94) |
| 2021 | $2,241 | 122 | AbbVie Inc. ($444.09) |
| 2020 | $1,585 | 113 | AstraZeneca Pharmaceuticals LP ($288.42) |
| 2019 | $1,343 | 80 | AstraZeneca Pharmaceuticals LP ($332.25) |
| 2018 | $1,500 | 100 | Novo Nordisk Inc ($372.26) |
| 2017 | $2,355 | 144 | Novo Nordisk Inc ($328.67) |
All Payment Transactions
906 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Cardio-renal | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Cardio-renal | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Cardio-renal | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: UROLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $84.61 | General |
| Category: VACCINES | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $20.78 | General |
| 11/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Cardio-renal | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Endocrinology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Cardio-renal | ||||||
| 10/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Diabetes Care | ||||||
| 10/10/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Inflammation | ||||||
| 10/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $6.90 | General |
| Category: Cardio-renal | ||||||
| 10/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Neuropsychiatry | ||||||
| 10/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 61 | 5,688 | 12,300 | $1.4M | $457,944 |
| 2022 | 60 | 5,885 | 12,417 | $1.4M | $453,864 |
| 2021 | 58 | 5,577 | 11,834 | $1.2M | $386,796 |
| 2020 | 49 | 5,307 | 10,233 | $1.1M | $350,169 |
Total Patients
22,457
Total Services
46,784
Medicare Billing
$1.6M
Procedure Codes
228
All Medicare Procedures & Services
228 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 253 | 692 | $114,872 | $58,456 | 50.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 135 | 725 | $113,100 | $44,128 | 39.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 102 | 467 | $97,136 | $42,696 | 44.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 231 | 231 | $43,890 | $28,561 | 65.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 75 | 640 | $102,400 | $23,094 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 213 | 367 | $40,003 | $22,319 | 55.8% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 102 | 222 | $62,160 | $21,185 | 34.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 53 | 333 | $43,290 | $14,692 | 33.9% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 69 | 421 | $54,730 | $12,710 | 23.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 62 | 148 | $23,828 | $11,669 | 49.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 64 | 290 | $58,000 | $10,149 | 17.5% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 59 | 183 | $23,790 | $9,979 | 41.9% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 301 | 658 | $67,774 | $8,620 | 12.7% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 34 | 41 | $14,491 | $8,599 | 59.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 192 | 277 | $24,376 | $8,036 | 33.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 339 | 941 | $20,702 | $7,896 | 38.1% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 98 | 106 | $43,460 | $7,783 | 17.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 26 | 26 | $8,060 | $7,341 | 91.1% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Office | 2023 | 70 | 74 | $11,988 | $7,327 | 61.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 53 | 53 | $14,681 | $7,104 | 48.4% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 333 | 842 | $63,992 | $6,961 | 10.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 328 | 786 | $40,086 | $5,974 | 14.9% |
| 80076 | Liver function blood test panel | Office | 2023 | 305 | 669 | $44,823 | $5,351 | 11.9% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2023 | 98 | 106 | $43,460 | $5,180 | 11.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 49 | 50 | $11,200 | $5,022 | 44.8% |
About Dr. Brenda Vozza, MD
Dr. Brenda Vozza, MD is a Internal Medicine healthcare provider based in Longview, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588616676.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brenda Vozza, MD has received a total of $15,247 in payments from pharmaceutical and medical device companies, with $1,934 received in 2024. These payments were reported across 906 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($15,126).
As a Medicare-enrolled provider, Vozza has provided services to 22,457 Medicare beneficiaries, totaling 46,784 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 228 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Longview, TX
- Active Since 05/17/2006
- Last Updated 05/26/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1588616676
Products in Payments
- Ozempic (Drug) $849.95
- Kerendia (Drug) $770.85
- FARXIGA (Drug) $749.23
- VRAYLAR (Drug) $678.66
- TRELEGY ELLIPTA (Drug) $574.28
- XIFAXAN (Drug) $489.69
- BREZTRI (Drug) $418.51
- ELIQUIS (Drug) $406.34
- XARELTO (Drug) $388.62
- TRULICITY (Drug) $375.58
- AREXVY (Drug) $372.75
- SYMBICORT (Drug) $350.81
- Victoza (Drug) $304.71
- ENTRESTO (Drug) $302.35
- JARDIANCE (Drug) $262.74
- EMGALITY (Drug) $253.89
- Rybelsus (Drug) $234.64
- SHINGRIX (Biological) $228.09
- Tresiba (Drug) $216.67
- UBRELVY (Drug) $196.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Longview
Dr. Matei Socoteanu, M.d, M.D
Internal Medicine — Payments: $43,107
Internal Medicine $43,107
Dr. Richard Kirkpatrick, M.d, M.D
Internal Medicine — Payments: $21,956
Internal Medicine $21,956
Dr. Justin Chen, M.d, M.D
Internal Medicine — Payments: $20,021
Internal Medicine $20,021
Dr. Helen Daniel-Glave, Md, MD
Internal Medicine — Payments: $8,759
Internal Medicine $8,759
Dr. Roger Pearce, Md, MD
Internal Medicine — Payments: $8,496
Internal Medicine $8,496
Dr. Jeffrey Hart, M.d, M.D
Internal Medicine — Payments: $8,443
Internal Medicine $8,443